About Avicella Capital
Avicella Capital is a venture capital firm founded in 2024. It is primarily based out of United States. As of Aug 2025, Avicella Capital has invested in 7 companies. It primarily invests in Series A round in Australia based startups. Its investments are spread across Life Sciences and Consumer sectors. Most recently it participated in the $***** Series A round of Faeth Therapeutics Overall, Avicella Capital portfolio has seen 1 acquisition, namely Faeth Therapeutics. A lot of funds co-invest with Avicella Capital, with names like UniSuper sharing a substantial percentage of its portfolio. Avicella Capital has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Series B
Portfolio Acquisitions
Avicella Capital's List of Top Investments
Avicella Capital has a portfolio of 7 companies. Their most notable investments are in Kinoxis Therapeutics and Convergence Medical.Their portfolio spans across Australia, United States, Netherlands and 1 more locations. They have invested in Life Sciences, Consumer, across Series A, Series B stages. Here is the list of top investments by Avicella Capital:Kinoxis Therapeutics is involved in the development of a range of therapeutic compounds for treating CNS disorders in collaboration with the University of Sydney. They are more focused on developing antiaddiction drugs, illicit, and prescription drugs. Their lead compound, SOC-1, which is an anti-addiction drug. It mimics the properties of the oxytocin hormone.
Key facts about Kinoxis Therapeutics
- Founded Year: 2017
- Location: Melbourne (Australia)
- Stage: Series B
- Total Funding till date: $18.2M
- Employee Count: 17 as on Aug 31, 2026
- Investors: UniSuper, The Australian health system and 6 Others
- Latest Funding Round: Series B, Sep 23, 2026, $*****
- Highlight: Editors' Pick
Provider of personalized nutritional programs against cancer. The company offers the Faeth program, a precision cancer treatment that uses metabolism to starve cancer cells, depriving and providing resistance to standard treatments. The program includes meals, therapeutics, and on-demand support from Faeth nutritionists.
Key facts about Faeth Therapeutics
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Acquired
- Total Funding till date: $92M
- Employee Count: 44 as on Aug 31, 2026
- Investors: Able Partners, iSelect Fund and 12 Others
- Latest Funding Round: Series A, Aug 01, 2025, $*****
- Highlight: Acquired
3. Eilean
Developer of small-molecule oncology therapies for hematologic malignancies. It offers small molecule therapies, including pan-variant FLT3 inhibitor and IRAK4 inhibitor that targets FLT3 mutations for treating acute myeloid leukemia.
Key facts about Eilean
- Founded Year: 2022
- Location: Dover (United States)
- Stage: Funding Raised
- Employee Count: 3 as on Aug 31, 2026
- Investors: Orbimed and Avicella Capital
4. Mondegobio
Developer of PTPN2 inhibitors for cancer immunotherapy with improved safety profile. The company focuses on immuno-oncological therapy by inhibiting PTPN2, enhancing IFNγ sensing and signaling. Their drug candidate exhibits strong PTPN2/PTPN1 inhibitory activity and selectivity against other phosphatases. It also demonstrates high oral bioavailability, good safety profiles, and induces tumor cells’ susceptibility to IFNγ.
Key facts about Mondegobio
- Founded Year: 2025
- Location: Cantanhede (Portugal)
- Stage: Series A
- Investors: Orbimed, Torrey Pines Investment and 2 Others
- Latest Funding Round: Series A, Sep 18, 2025, $*****
Developer of robots for arthroscopic surgery. The company's product includes the V01 an arthroscopic robot to make minimally invasive surgery better.
Key facts about Convergence Medical
- Founded Year: 2022
- Location: Brisbane (Australia)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $3.1M
- Employee Count: 19 as on Aug 31, 2026
- Investors: Avicella Capital and Summit Capital
- Latest Funding Round: Series A, Jan 16, 2025, $*****
- Highlight: Editors' Pick
Avicella Capital's Year-on-Year Investment Trends
In 2025, it made 2 investments. Its most recent first time investment was in Faeth Therapeutics.Avicella Capital's Investments by Stage
Avicella Capital has made 2 investments in Series A stage with an average round size of $14.1M and 1 investment in Series B stage with an average round size of $9.55M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series B | 1 |
Note: We have considered here, only first round of investments
Avicella Capital's Investments by Sector
Avicella Capital has a diverse portfolio, with companies operating in the Life Sciences and Consumer. Notably, it has invested in 7 Tech companies, 5 Enterprise (B2B) companies, 1 Consumer (B2C) company and at least 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 3 |
Consumer | 1 |
Note: We have considered here, only first round of investments
Avicella Capital's Investments by Geography
Avicella Capital has made most investments in Australia (2), followed by United States where it has made 1 investment.Country | No. of Investments |
|---|---|
Australia | 2 |
United States | 1 |
Note: We have considered here, only first round of investments
Avicella Capital's recent investments
Avicella Capital has not made any investment in 2026 so far.Here are the most recent investments by Avicella Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 01, 2025 | United States | Series A | 2916 | [+7] | |
Jan 16, 2025 | Australia | Series A | 7174 | - | |
Aug 13, 2024 | Australia | Series B | 6396 | [+3] |
Acquired companies in Avicella Capital's Portfolio
1 company from Avicella Capital's portfolio has been acquired. The most recent acquisition was Faeth Therapeutics in Feb 2026 by Sensei Biotherapeutics for $*****.Here are Avicella Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 18, 2026 | Aug 01, 2025 | Series A | 9609 |
Team profile of Avicella Capital
Avicella Capital has a team of 2 members including 2 Partners located in France and United States. Avicella Capital's team does not sit on the board of any company as of now.Co-investors of Avicella Capital
Over the past 2 years, 17 investors have co-invested in Avicella Capital's portfolio companies. This includes only funds.
- Invested before Avicella Capital: Uniseed, NIH and 8 others have invested in rounds before Avicella Capital. There is 1 company where Uniseed has invested before Avicella Capital and 1 company where NIH has invested before Avicella Capital.
- Top Co-investors of Avicella Capital: 5 investors entered a company along with Avicella Capital. These include investors like UniSuper (1 company).
- Invested after Avicella Capital: Main Sequence (1 company) and The Australian health system (1 company) are the investors which have invested in Avicella Capital's portfolio after their investments.
Recent News related to Avicella Capital
•
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial CancerBakersfield•Oct 21, 2025•S2G Investments, Avicella Capital, Faeth Therapeutics, B Capital and 4 others
•
Faeth nets $25M for endometrial cancer study.Endpoints•Oct 19, 2025•Faeth Therapeutics, S2G Investments, Avicella Capital, B Capital and 6 others
•
Brisbane medtech company secures $5M for surgical robotAustralian Manufacturing•Jan 21, 2025•Convergence Medical, Avicella Capital, Brisbane Economic Development Agency
•
Arthroscopic robot developer Convergence Medical seals $5m Series A, boosting its valuation to $30mBusiness News Australia Pty Ltd•Jan 16, 2025•Convergence Medical, Avicella Capital
•
Sydney Uni mental health biotech banks $14.5 million Series BStartup Daily•Aug 13, 2024•Kinoxis Therapeutics, Uniseed, UniSuper, Stoic Venture Capital and 1 other
